281 related articles for article (PubMed ID: 25487422)
41. Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.
Ghonim AE; Ligresti A; Rabbito A; Mahmoud AM; Di Marzo V; Osman NA; Abadi AH
Eur J Med Chem; 2019 Oct; 180():154-170. PubMed ID: 31302448
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells.
Gado F; Ferrisi R; Di Somma S; Napolitano F; Mohamed KA; Stevenson LA; Rapposelli S; Saccomanni G; Portella G; Pertwee RG; Laprairie RB; Malfitano AM; Manera C
Molecules; 2022 May; 27(9):. PubMed ID: 35566369
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
[TBL] [Abstract][Full Text] [Related]
44. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.
Yang JF; Williams AH; Penthala NR; Prather PL; Crooks PA; Zhan CG
ACS Chem Neurosci; 2020 Oct; 11(20):3455-3463. PubMed ID: 32997485
[TBL] [Abstract][Full Text] [Related]
45. Development of
Intranuovo F; Brunetti L; DelRe P; Mangiatordi GF; Stefanachi A; Laghezza A; Niso M; Leonetti F; Loiodice F; Ligresti A; Kostrzewa M; Brea J; Loza MI; Sotelo E; Saviano M; Colabufo NA; Riganti C; Abate C; Contino M
J Med Chem; 2023 Jan; 66(1):235-250. PubMed ID: 36542836
[TBL] [Abstract][Full Text] [Related]
46. Chronic activation of cannabinoid receptors in vitro does not compromise mouse islet function.
Vilches-Flores A; Hauge-Evans AC; Jones PM; Persaud SJ
Clin Sci (Lond); 2013 Apr; 124(7):467-78. PubMed ID: 23078523
[TBL] [Abstract][Full Text] [Related]
47. CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.
Christie S; Zagorodnyuk V
Am J Physiol Renal Physiol; 2021 May; 320(5):F859-F865. PubMed ID: 33749323
[TBL] [Abstract][Full Text] [Related]
48. Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists.
Yrjölä S; Kalliokoski T; Laitinen T; Poso A; Parkkari T; Nevalainen T
Eur J Pharm Sci; 2013 Jan; 48(1-2):9-20. PubMed ID: 23131798
[TBL] [Abstract][Full Text] [Related]
49. The Leu/Val
Llinas Del Torrent C; Raïch I; Gonzalez A; Casajuana-Martin N; Lillo J; Rebassa JB; Ferreiro-Vera C; Sánchez de Medina V; Franco R; Navarro G; Pardo L
J Chem Inf Model; 2023 Sep; 63(18):5927-5935. PubMed ID: 37644761
[TBL] [Abstract][Full Text] [Related]
50. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R).
Graziano G; Delre P; Carofiglio F; Brea J; Ligresti A; Kostrzewa M; Riganti C; Gioè-Gallo C; Majellaro M; Nicolotti O; Colabufo NA; Abate C; Loza MI; Sotelo E; Mangiatordi GF; Contino M; Stefanachi A; Leonetti F
Eur J Med Chem; 2023 Feb; 248():115109. PubMed ID: 36657299
[TBL] [Abstract][Full Text] [Related]
51. Structure-Based Virtual Screening and Molecular Dynamics Simulation Assessments of Depsidones as Possible Selective Cannabinoid Receptor Type 2 Agonists.
Mohamed GA; Omar AM; AlKharboush DF; Fallatah MA; Sindi IA; El-Agamy DS; Ibrahim SRM
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838749
[TBL] [Abstract][Full Text] [Related]
52. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency.
Smoum R; Baraghithy S; Chourasia M; Breuer A; Mussai N; Attar-Namdar M; Kogan NM; Raphael B; Bolognini D; Cascio MG; Marini P; Pertwee RG; Shurki A; Mechoulam R; Bab I
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8774-9. PubMed ID: 26124120
[TBL] [Abstract][Full Text] [Related]
53. Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.
Yang P; Wang L; Feng R; Almehizia AA; Tong Q; Myint KZ; Ouyang Q; Alqarni MH; Wang L; Xie XQ
J Med Chem; 2013 Mar; 56(5):2045-58. PubMed ID: 23406429
[TBL] [Abstract][Full Text] [Related]
54. A Novel Selective Inverse Agonist of the CB
Martella A; Sijben H; Rufer AC; Grether U; Fingerle J; Ullmer C; Hartung T; IJzerman AP; van der Stelt M; Heitman LH
Mol Pharmacol; 2017 Oct; 92(4):389-400. PubMed ID: 28747489
[TBL] [Abstract][Full Text] [Related]
55. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
56. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
57. Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.
Janero DR; Yaddanapudi S; Zvonok N; Subramanian KV; Shukla VG; Stahl E; Zhou L; Hurst D; Wager-Miller J; Bohn LM; Reggio PH; Mackie K; Makriyannis A
ACS Chem Neurosci; 2015 Aug; 6(8):1400-10. PubMed ID: 25978068
[TBL] [Abstract][Full Text] [Related]
58. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
59. Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors.
El-Atawneh S; Goldblum A
Front Pharmacol; 2022; 13():812745. PubMed ID: 35295337
[TBL] [Abstract][Full Text] [Related]
60. Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias.
Sharma R; Singh S; Whiting ZM; Molitor M; Vernall AJ; Grimsey NL
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]